May. 7 at 12:13 AM
$BCTX The Bria-OTS trial that resulted in the complete resolution of the lung metastases was conducted with the BC1 cell line (as monotherapy and no CPI). This cell line is the same as that used in the P3 trial, but with new HLA-A and HLA-DRB expressions (along with the interferon alpha and GM-CSF expressions). You'll find it on the poster here: https://2f04c740.delivery.rocketcdn.me/wp-content/uploads/2022/04/AACR_Poster_BriaCell_2022April12.pdf
This new therapy will include new, patient-matching HLA types, as well as adding more cytokines and costimulatory molecules. This includes IL-7, IL-12, CD80, CD86 and CD40/CD40L. Each of these additional expressions are expected to further enhance and support immune activation against the cancer cells.
Now, if they can just get the prostate therapy approved for trials, then they'll have a true multi-indication platform that isn't based entirely on one unique cell line.
